Tenvie Therapeutics announced that it recently launched with a commitment to transform the treatment of neurological diseases. And the company raised $200 million in funding led by ARCH Venture Partners, F-Prime Capital, Mubadala Capital, with participation from additional high-quality investors. This funding will accelerate Tenvie’s growth into a multi-clinical asset company.
The company combines a deep and diverse portfolio of small molecule assets, including programs acquired from Denali Therapeutics Inc., with a proven team of research and development leaders.
Tenvie is creating a portfolio of wholly owned, highly brain-penetrant and peripherally restricted small molecules that address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function. And its most advanced programs, an NLRP3 inhibitor and an allosteric SARM1 inhibitor, are in the IND-enabling stage. Tenvie’s diverse pipeline includes programs focused on neuroprotective pathways, including TRPML1 and TMEM175.
Tenvie has put together a team of experts across neurology and CNS drug development, small molecule chemistry, neurobiology, translational medicine, and business operations. And the company’s leadership team and Board of Directors includes
— Tony Estrada, Ph.D., President, Chief Scientific Officer and Board Director
— Brian Cuneo, J.D., Chief Business and Legal Officer
— Tanya Fischer, M.D., Ph.D., Chief Medical Officer
— Paul L. Berns, Executive Chair of Tenvie’s Board, Managing Director, ARCH Venture Partners
— Kristina Burow, Tenvie Board Director, Managing Director, ARCH Venture Partners
— Alaa Halawa, Tenvie Board Director, Head of Healthcare and Executive Director, Mubadala Capital
— Joe Lewcock, Ph.D., Tenvie Board Director, Chief Scientific Officer, Denali Therapeutics
— Stacie Weninger, Ph.D., Tenvie Board Director, President, FBRI, Venture Partner, F-Prime Capital
KEY QUOTES:
“Tenvie was founded to fundamentally alter the treatment paradigm for neurological diseases and profoundly impact the lives of patients, their families, and caregivers. Our team’s validated approach uniquely allows us to access the brain while enabling the parallel development of precision-designed peripherally-restricted small molecules to address a broad array of diseases.”
– Tony Estrada, Ph.D., President and Chief Scientific Officer at Tenvie
“Tenvie was purpose-built to apply deep biological and chemical insights to address critical disease pathways. Tenvie’s promise is to unlock the therapeutic potential of small molecules to address key drivers of both central and peripheral diseases.”
– Paul L. Berns, Managing Director at ARCH Venture Partners and Executive Chair of Tenvie
“There remains an urgent need for neurological treatments that provide durable therapeutic benefit and fill the gaps in care for diseases with limited or no effective therapies. Led by CNS drug developers with proven track records in advancing molecules from discovery to clinical validation, Tenvie is set to lead the next generation of neurology treatments.”
– Stacie Weninger, Venture Partner at F-Prime Capital
